PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
In a highly competitive process, MultiplexDX received a prestigious Seal of Excellence from the European Commission managing Horizon 2020 program for research and innovation 2014-2020. An international panel of independent experts evaluated Multiplex9 as a high-quality project proposal recommended for funding. Multiplex9 is a revolutionary highly accurate cancer diagnostic test for assessment of both therapy response and personalized prognosis.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
"For us, it's a great proof that our project, business plan, commercialization strategy and team are very innovative and bound to be successful! We're now on the last round of fundraising and soon going to proceed to our next stage of development."
More importantly, this year MultiplexDX H2020 SME instrument phase 2 submission got the highest (above 4 threshold) score for impact, excellence and implementation. Such a high evaluation from the European Commission experts will significantly increase the company's chances to be awarded with € 2,8 mil. SME grant in the next round.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.